| Name | Title | Contact Details |
|---|---|---|
Charles Bradley |
Managing Director Strategic Planning & Customer Service | Profile |
Michelle Daniels |
Vice President - Product Strategy, Development and Administration | Profile |
Steve Berg |
Vice President of Product Strategy and Development, Healthcare Textiles | Profile |
Janet Mead |
Human Resources Executive | Profile |
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Fisher Micro is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical DecisionPoint is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rovin Med, is a Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amirsys, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Salt Lake City, UT. To find more information about Amirsys, Inc., please visit www.amirsys.com